An open label, single arm study to assess the safety and immunogenicity of omalizumab liquid administered subcutaneously in a pre-filled safety syringe (75 mg or 150 mg) over a period of 6 months to male and female adolescents and adults with moderate to severe persistent allergic asthma

Trial Profile

An open label, single arm study to assess the safety and immunogenicity of omalizumab liquid administered subcutaneously in a pre-filled safety syringe (75 mg or 150 mg) over a period of 6 months to male and female adolescents and adults with moderate to severe persistent allergic asthma

Completed
Phase of Trial: Phase III

Latest Information Update: 25 Nov 2014

At a glance

  • Drugs Omalizumab (Primary)
  • Indications Allergic asthma
  • Focus Pharmacodynamics; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 26 Apr 2011 Actual end date (1 Sep 2008) added as reported by ClinicalTrials.gov.
    • 26 Apr 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 13 Aug 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top